Wayfinder Biosciences is a biotechnology company developing orally available small-molecule drugs that modulate RNA-encoded disease targets. It describes a platform combining screening and computational technologies to discover selective RNA-targeting molecules, with programs in oncology and neurodegenerative disease. The company is based in Seattle and identifies as privately held.
Pharmaceutical companies are increasingly partnering with biotechs developing RNA-targeting small molecules, driven by advances in RNA structural biology and the success of drugs like Roche's Evrysdi. The approach aims to address "undruggable" targets while offering oral availability advantages.
Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.
